CR11359A - Derivados de pirrolo (2,3-d) pirimidina como inhibidores de proteinas quinasa b - Google Patents

Derivados de pirrolo (2,3-d) pirimidina como inhibidores de proteinas quinasa b

Info

Publication number
CR11359A
CR11359A CR11359A CR11359A CR11359A CR 11359 A CR11359 A CR 11359A CR 11359 A CR11359 A CR 11359A CR 11359 A CR11359 A CR 11359A CR 11359 A CR11359 A CR 11359A
Authority
CR
Costa Rica
Prior art keywords
quinase
pyrimidine
inhibitors
proteins
pirrolo
Prior art date
Application number
CR11359A
Other languages
English (en)
Inventor
Paul David Johnson
Andrew Leach
Richard William Arthur Luke
Zbigniew Stanley Matusiak
Jeffrey James Morris
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40251789&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR11359(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CR11359A publication Critical patent/CR11359A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La invencion se refiere a un grupo novedoso de compuestos de Formula (I) o sus sales: en la que Y, Z1, Z2, R1, R4, R5 y n son como se han descrito en la memoria descriptiva, que pueden ser utiles en el tratamiento o prevencion de una enfermedad o afeccion medica mediada por la proteina quinasa B (PKB) tal como cancer.
CR11359A 2007-10-11 2010-04-09 Derivados de pirrolo (2,3-d) pirimidina como inhibidores de proteinas quinasa b CR11359A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97919207P 2007-10-11 2007-10-11
US4786208P 2008-04-25 2008-04-25

Publications (1)

Publication Number Publication Date
CR11359A true CR11359A (es) 2010-07-15

Family

ID=40251789

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11359A CR11359A (es) 2007-10-11 2010-04-09 Derivados de pirrolo (2,3-d) pirimidina como inhibidores de proteinas quinasa b

Country Status (43)

Country Link
US (8) US8101623B2 (es)
EP (1) EP2201012B1 (es)
JP (2) JP4705695B2 (es)
KR (1) KR101494734B1 (es)
CN (1) CN101861321B (es)
AR (1) AR068846A1 (es)
AU (1) AU2008309383B2 (es)
BR (1) BRPI0818533B8 (es)
CA (1) CA2701057C (es)
CL (1) CL2008003023A1 (es)
CO (1) CO6270328A2 (es)
CR (1) CR11359A (es)
CU (1) CU23886B1 (es)
CY (2) CY1116929T1 (es)
DK (1) DK2201012T3 (es)
DO (1) DOP2010000103A (es)
EA (1) EA018512B1 (es)
ES (1) ES2522365T3 (es)
FI (1) FIC20240039I1 (es)
FR (1) FR24C1046I2 (es)
GT (1) GT201000082A (es)
HN (1) HN2010000653A (es)
HR (1) HRP20140807T1 (es)
HU (1) HUS2400038I1 (es)
IL (1) IL204721A (es)
LT (1) LTC2201012I2 (es)
ME (1) ME01999B (es)
MX (1) MX2010003927A (es)
MY (1) MY150059A (es)
NI (1) NI201000050A (es)
NL (1) NL301299I2 (es)
NO (1) NO2024050I1 (es)
NZ (1) NZ585261A (es)
PE (2) PE20090964A1 (es)
PL (1) PL2201012T3 (es)
PT (1) PT2201012E (es)
RS (1) RS53552B1 (es)
SA (1) SA08290625B1 (es)
SI (1) SI2201012T1 (es)
TW (1) TWI453021B (es)
UY (1) UY31384A1 (es)
WO (1) WO2009047563A1 (es)
ZA (1) ZA201002318B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
WO2007125321A2 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
WO2008018642A2 (en) * 2006-08-10 2008-02-14 Oncotherapy Science, Inc. Genes and polypeptides relating to breast cancers
PL2201012T3 (pl) 2007-10-11 2014-11-28 Astrazeneca Ab Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinazy białkowej b
WO2011002772A1 (en) * 2009-06-29 2011-01-06 Oncotherapy Science, Inc. Imidazopyridine derivatives and pbk inhibitors containing the same
GB201020161D0 (en) 2010-11-26 2011-01-12 Almac Discovery Ltd Pharmaceutical compounds
EP2651417B1 (en) 2010-12-16 2016-11-30 Calchan Limited Ask1 inhibiting pyrrolopyrimidine derivatives
JP6100700B2 (ja) 2011-01-11 2017-03-22 ノバルティス アーゲー 組合せ
EP2694056B1 (en) * 2011-04-01 2019-10-16 AstraZeneca AB Therapeutic treatment
PH12014500943A1 (en) * 2011-11-30 2014-06-30 Astrazeneca Ab Combination treatment of cancer
AU2013204533B2 (en) * 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
MA38287B1 (fr) 2013-01-23 2018-08-31 Astrazeneca Ab Nouveaux dérivés aminopyrazine pour le traitement ou la prévention du cancer
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
CN105764501A (zh) 2013-07-26 2016-07-13 现代化制药公司 改善比生群治疗效益的组合物
JP6295578B2 (ja) * 2013-09-30 2018-03-20 凸版印刷株式会社 反応容器、核酸解析装置、および核酸解析方法
ES3063787T3 (en) * 2013-10-01 2026-04-20 Novartis Ag Composition comprising a 17 a-hydroxylase/c17,20 lyase (cyp17a1) inhibitor and an akt inhibitor
SI3105218T1 (sl) 2014-02-13 2019-11-29 Incyte Corp Ciklopropilamini kot inhibitorji LSD1
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
EP3105219B9 (en) 2014-02-13 2018-10-03 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
MX373103B (es) 2014-02-13 2020-04-17 Incyte Holdings Corp Ciclopropilaminas como inhibidores de desmetilasa específica de lisina 1 (lsd1).
RU2674027C2 (ru) * 2014-05-28 2018-12-04 Астразенека Аб Способ получения AZD5363 (варианты) и применяемое в нем новое промежуточное соединение
TWI687419B (zh) 2014-07-10 2020-03-11 美商英塞特公司 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
TW201613925A (en) 2014-07-10 2016-04-16 Incyte Corp Imidazopyrazines as LSD1 inhibitors
EP3277689B1 (en) 2015-04-03 2019-09-04 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
LT3334709T (lt) 2015-08-12 2025-03-10 Incyte Holdings Corporation Lsd1 inhibitoriaus druskos
TW201726140A (zh) 2015-09-17 2017-08-01 瑞典商阿斯特捷利康公司 治療癌症之新型生物標記及方法
JP6999574B2 (ja) 2016-04-22 2022-01-18 インサイト・コーポレイション Ｌｓｄ１阻害剤の製剤
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
IL320609A (en) 2019-08-26 2025-07-01 Arvinas Operations Inc Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents
CA3158321A1 (en) 2019-11-04 2021-05-14 Astrazeneca Ab Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies
TWI908780B (zh) * 2020-03-17 2025-12-21 大陸商江蘇恆瑞醫藥股份有限公司 稠合二環類衍生物、其製備方法及其在醫藥上的應用
EP4271678A1 (en) * 2021-01-04 2023-11-08 Teva Pharmaceuticals International GmbH Solid state forms of capivasertib and process for preparation thereof
CN116925080B (zh) * 2022-03-29 2025-12-12 杭州健崃生物科技有限公司 作为Akt蛋白激酶抑制剂的化合物及其制备方法和用途
IL315848A (en) 2022-03-31 2024-11-01 Astrazeneca Ab Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in combination with an AKT inhibitor for cancer treatment
CN114601836B (zh) * 2022-04-12 2022-12-06 四川大学华西医院 一种akt抑制剂在制备治疗乳腺癌的药物中的应用
WO2024083716A1 (en) 2022-10-17 2024-04-25 Astrazeneca Ab Combinations of a serd for the treatment of cancer
EP4615431A1 (en) 2022-11-11 2025-09-17 Astrazeneca AB Combination therapies for the treatment of cancer
CN120202006A (zh) 2022-11-15 2025-06-24 阿斯利康(瑞典)有限公司 卡帕塞替尼和维奈托克的治疗组合
AU2024279893A1 (en) 2023-05-26 2026-01-22 Astrazeneca Ab Pharmaceutical compositions
EP4719399A1 (en) 2023-06-02 2026-04-08 Arvinas Operations, Inc. Combinations of estrogen receptor degraders and akt inhibitors
TW202533828A (zh) 2024-02-22 2025-09-01 瑞典商阿斯特捷利康公司 Ａｋｔ抑制劑、ｂｃｌ－２抑制劑、及抗ｃｄ２０抗體之治療組合
WO2025238662A1 (en) * 2024-05-15 2025-11-20 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of 4-amino-n-[(1s)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4-piperidinecarboxamide and its salts
WO2026057582A1 (en) 2024-09-10 2026-03-19 Astrazeneca Ab Therapeutic combinations of an akt inhibitor, a bcl-2 inhibitor, and a glucocorticoid

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE637271A (es) 1963-04-04 1900-01-01
GB9312853D0 (en) 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
BR9707495A (pt) 1996-02-13 1999-07-27 Zeneca Ltd Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente
US6291455B1 (en) 1996-03-05 2001-09-18 Zeneca Limited 4-anilinoquinazoline derivatives
JP2001519766A (ja) 1996-04-03 2001-10-23 メルク エンド カンパニー インコーポレーテッド ファルネシルタンパク質トランスフェラーゼの阻害剤
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
DE69837529T2 (de) 1997-02-12 2007-07-26 Electrophoretics Ltd., Cobham Proteinmarker für lungenkrebs und deren verwendung
US6432947B1 (en) 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
ID24300A (id) 1997-08-05 2000-07-13 Pfizer Prod Inc 4-AMINOPIROL(3,2-d)PIRIMIDIN SEBAGAI ANTAGONIS-ANTAGONIS RESEPTOR NEUROPEPTIDA Y
US6162804A (en) 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
CA2333770A1 (en) 1998-06-04 1999-12-09 Abbott Laboratories Cell adhesion-inhibiting antinflammatory compounds
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
SK288365B6 (sk) 1999-02-10 2016-07-01 Astrazeneca Ab Medziprodukty pre chinazolínové deriváty ako inhibítory angiogenézy
WO2000075145A1 (en) 1999-06-03 2000-12-14 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
CZ301689B6 (cs) 1999-11-05 2010-05-26 Astrazeneca Ab Derivát chinazolinu a farmaceutický prostredek, který ho obsahuje
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
SI1255752T1 (sl) 2000-02-15 2007-12-31 Pharmacia & Upjohn Co Llc S pirolom substituirani zaviralci 2-indolinon protein kinaza
NZ522074A (en) 2000-05-31 2004-06-25 Astrazeneca Ab Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
IL152771A0 (en) 2000-06-26 2003-06-24 Pfizer Prod Inc PYRROLO(2,3-d) PYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE AGENTS
IL153484A0 (en) 2000-07-07 2003-07-06 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors
CN1255392C (zh) 2000-07-07 2006-05-10 安吉奥金尼药品有限公司 作为血管生成抑制剂的秋水仙醇衍生物
BR0113585A (pt) 2000-08-31 2003-07-29 Hoffmann La Roche Derivados quinazolina como antagonistas adrenérgicos alfa-1
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
AP1893A (en) 2000-12-01 2008-09-23 Osi Pharm Inc Compounds specific to adenosine A1, A2A and A3 receptor and uses thereof
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
JP2004532234A (ja) * 2001-04-27 2004-10-21 バーテックス　ファーマシューティカルズ　インコーポレイテッド トリアゾール由来キナーゼインヒビターおよびその使用
AU2003235741B8 (en) 2002-01-07 2009-01-15 Eisai R&D Management Co., Ltd. Deazapurines and uses thereof
TW200403058A (en) 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
DK1522314T3 (da) 2002-06-26 2014-05-26 Ono Pharmaceutical Co Midler for sygdomme forårsaget af vaskulær sammentrækning eller udvidelse
US20040138238A1 (en) 2002-08-08 2004-07-15 Dhanoa Dale S. Substituted aminopyrimidine compounds as neurokinin antagonists
US20030139427A1 (en) 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
AU2003265636A1 (en) 2002-09-06 2004-03-29 Smithkline Beecham Corporation Pyrrolo(2, 3-d)pyrimidine-4-yl and purin-6-yl urea compounds
JP4796301B2 (ja) 2002-11-08 2011-10-19 プレジデント アンド フェロウズ オブ ハーバード カレッジ テクネチウム−９９ｍ及びレニウムで標識した小型作用剤及び組織、臓器及び腫瘍の画像化方法
JP4279784B2 (ja) 2002-12-04 2009-06-17 エーザイ・アール・アンド・ディー・マネジメント株式会社 １，３−ジヒドロ−イミダゾール縮合環化合物
EP1444982A1 (de) 2003-02-06 2004-08-11 Merckle Gmbh Verwendung von Purinderivaten als selektive Kinase-Inhibitoren
MXPA05009722A (es) 2003-03-10 2006-03-09 Schering Corp Inhibidores heterociclicos de cinasa: metodos de uso y sintesis.
EP1615926A1 (en) 2003-04-21 2006-01-18 Ustav Organicke Chemie A Biochemie Akademie Ved Ceske Republiky (purin-6-yl) amino acid and production method thereof
FR2856685B1 (fr) 2003-06-25 2005-09-23 Merck Sante Sas Derives de thiazolylpiperidine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
EP1663204B1 (en) 2003-08-29 2014-05-07 Exelixis, Inc. C-kit modulators and methods of use
WO2005044181A2 (en) 2003-09-09 2005-05-19 Temple University-Of The Commonwealth System Of Higher Education Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
TW200526626A (en) 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
CA2546754A1 (en) 2003-11-21 2005-06-09 Array Biopharma Inc. Akt protein kinase inhibitors
WO2005063704A1 (ja) 2003-12-25 2005-07-14 Ono Pharmaceutical Co., Ltd. アゼチジン環化合物およびその医薬
MXPA06010520A (es) * 2004-03-30 2007-03-26 Chiron Corp Derivados de tiofeno sustituidos como agentes anticancerosos.
WO2005117909A2 (en) * 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
UY29177A1 (es) * 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
CA2590961C (en) * 2004-12-28 2013-11-26 Exelixis, Inc. [1h-pyrazolo[3,4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases
FR2880626B1 (fr) 2005-01-13 2008-04-18 Aventis Pharma Sa Derives de la purine, compositions les contenant et utilisation
FR2880540B1 (fr) 2005-01-13 2008-07-11 Aventis Pharma Sa Utilisation de derives de la purine comme inhibiteurs de la proteine hsp90
US7423043B2 (en) 2005-02-18 2008-09-09 Lexicon Pharmaceuticals, Inc. 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds
US20060281768A1 (en) 2005-06-10 2006-12-14 Gaul Michael D Thienopyrimidine and thienopyridine kinase modulators
WO2007007919A2 (en) 2005-07-14 2007-01-18 Astellas Pharma Inc. Heterocyclic janus kinase 3 inhibitors
WO2007025090A2 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
US20070208053A1 (en) 2006-01-19 2007-09-06 Arnold Lee D Fused heterobicyclic kinase inhibitors
JP2009534454A (ja) 2006-04-25 2009-09-24 アステックス、セラピューティックス、リミテッド 医薬化合物
EP2029592A1 (en) * 2006-04-25 2009-03-04 Astex Therapeutics Limited Pharmaceutical compounds
WO2007125321A2 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
WO2007125315A2 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Pharmaceutical compounds
EP2037931A2 (en) 2006-04-25 2009-03-25 Astex Therapeutics Limited Pharmaceutical combinations of pk inhibitors and other active agents
AR064415A1 (es) 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de pirrolo-piperidinas y purinas,composiciones farmaceuticas que los contienen y usos en trastornos y/o enfermedades mediadas por pka y pkb.
AR064416A1 (es) 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
AU2007338754A1 (en) 2006-12-21 2008-07-03 Vertex Pharmaceuticals Incorporated 5-cyan0-4- (pyrrolo [2, 3B] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors
PL2201012T3 (pl) 2007-10-11 2014-11-28 Astrazeneca Ab Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinazy białkowej b

Also Published As

Publication number Publication date
US10654855B2 (en) 2020-05-19
US20240109902A1 (en) 2024-04-04
FR24C1046I2 (fr) 2025-10-10
IL204721A0 (en) 2010-11-30
NL301299I2 (nl) 2024-12-11
EA018512B1 (ru) 2013-08-30
JP2011157364A (ja) 2011-08-18
HUS2400038I1 (hu) 2024-12-28
EP2201012A1 (en) 2010-06-30
KR20100101077A (ko) 2010-09-16
FR24C1046I1 (fr) 2025-01-10
PT2201012E (pt) 2014-09-04
US9492453B2 (en) 2016-11-15
ES2522365T3 (es) 2014-11-14
US10059714B2 (en) 2018-08-28
KR101494734B1 (ko) 2015-02-26
CL2008003023A1 (es) 2009-11-27
MY150059A (en) 2013-11-29
SA08290625B1 (ar) 2012-02-12
JP5330430B2 (ja) 2013-10-30
DK2201012T3 (da) 2014-09-08
US20120190679A1 (en) 2012-07-26
GT201000082A (es) 2015-03-10
PL2201012T3 (pl) 2014-11-28
US20220220116A1 (en) 2022-07-14
PE20130152A1 (es) 2013-03-17
ME01999B (me) 2015-05-20
IL204721A (en) 2013-10-31
BRPI0818533A2 (pt) 2017-06-06
PE20090964A1 (es) 2009-08-15
US12252495B2 (en) 2025-03-18
HK1143154A1 (en) 2010-12-24
CN101861321A (zh) 2010-10-13
US20200239483A1 (en) 2020-07-30
CN101861321B (zh) 2013-02-06
AU2008309383A1 (en) 2009-04-16
ZA201002318B (en) 2012-09-26
US20090163524A1 (en) 2009-06-25
CO6270328A2 (es) 2011-04-20
US20150182531A1 (en) 2015-07-02
CU20100062A7 (es) 2011-10-05
MX2010003927A (es) 2010-04-30
BRPI0818533B1 (pt) 2020-12-01
US20170057969A1 (en) 2017-03-02
UY31384A1 (es) 2009-05-29
CY1116929T1 (el) 2017-04-05
JP4705695B2 (ja) 2011-06-22
CU23886B1 (es) 2013-04-19
HN2010000653A (es) 2013-03-18
FIC20240039I1 (fi) 2024-11-12
CY2024030I1 (el) 2026-02-25
NZ585261A (en) 2011-10-28
JP2011500547A (ja) 2011-01-06
AU2008309383B2 (en) 2012-04-19
US8101623B2 (en) 2012-01-24
HRP20140807T1 (hr) 2014-11-21
EP2201012B1 (en) 2014-06-25
EA201000552A1 (ru) 2010-12-30
AR068846A1 (es) 2009-12-09
LTC2201012I2 (es) 2025-12-10
TWI453021B (zh) 2014-09-21
US11236095B2 (en) 2022-02-01
US11760760B2 (en) 2023-09-19
LTPA2024532I1 (es) 2024-12-10
WO2009047563A1 (en) 2009-04-16
TW200927128A (en) 2009-07-01
CY2024030I2 (el) 2026-02-25
NO2024050I1 (no) 2024-11-18
CA2701057C (en) 2015-03-24
CA2701057A1 (en) 2009-04-16
NI201000050A (es) 2011-12-22
SI2201012T1 (sl) 2014-10-30
BRPI0818533B8 (pt) 2021-05-25
DOP2010000103A (es) 2010-05-31
US20180312516A1 (en) 2018-11-01
RS53552B1 (sr) 2015-02-27

Similar Documents

Publication Publication Date Title
CR11359A (es) Derivados de pirrolo (2,3-d) pirimidina como inhibidores de proteinas quinasa b
UY29458A1 (es) Heterociclos sustituidos y usos de los mismos
CY1123625T1 (el) Συνθεσεις και μεθοδοι για θεραπεια διαταραχων χρησης αλκοολης, πονου και αλλων ασθενειων
UY30779A1 (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa
ECSP10010599A (es) Derivados de tienopiridonas como activadores de proteina quinasa activados por amp (ampk)
UY32302A (es) Carboxamidas heterobicíclicas como inhibidoras de cinasas
ATE502038T1 (de) Azyklische amininhibitoren von nukleosidphosphorylasen und hydrolasen
PE20141855A1 (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
CL2008002130A1 (es) Compuestos derivados de 2-amino-cromen-4-ona; composicion farmaceutica que lo comprende; y uso en el tratamiento de una enfermedad que es aliviada por la inhibicion de la proteina quinasa dependiente de adn (adn-pk), tal como cancer.
UA111588C2 (uk) Композиція інгібітора jak для місцевого застосування
CR11554A (es) Pirrolo-Pirimidinas y Pirrolo-Piridinas
CR11614A (es) Pirrolo[2,3-d]piridinas y usos de las mismas como inhibidores de cinasa de tirosina
CY1112453T1 (el) Αντιϊικες ενωσεις
BRPI0915084B8 (pt) composto, e, composição farmacêutica
UY30282A1 (es) Compuestos quimicos
CO6331304A2 (es) Derivados de tienopiridonas como activadores de proteina quinasa activados por amp (ampk)
GT200800285A (es) Aminopirazolopiridinas sustituidas y sus sales, sus preparaciones y composiciones farmaceuticas que las comprenden
CY1114140T1 (el) Ενωσεις 4-πυριδινονης και η χρηση αυτων για τον καρκινο
EA201000614A1 (ru) Производные пурина как лиганды аденозинового рецептора а
CR10304A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
MX385354B (es) Sales de xantilio 3,6-disustituidas.
CL2007001748A1 (es) Compuesto derivado de 2-arilamino-4-aminopirimidinas, inhibidores de la proteina quinasa c-alfa; composiciones farmaceuticas que los contienen; y su uso para tratar o prevenir la diabetes, el cancer, enfermedades cardiovasculares y otras.
DOP2006000061A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
EA200801425A1 (ru) Диазепиноны
DOP2006000248A (es) Acido 1-(1-(2-etoxietil)-3-etil-7-(4-metilpiridin-2-ilamino)-1h- pirazolo[4,3-d]pirimidin-5-il)piperidina-4-carboxílico y las sales del mismo.